Description

B7-33 is an innovative synthetic research compound developed by scientists at Monash University in Australia. It was designed as a selective agonist of the relaxin family peptide receptor 1 (RXFP1), meaning it can activate this receptor in a targeted and controlled manner.

In laboratory settings, B7-33 is used in research focused on the cardiovascular and renal systems, as well as inflammatory processes. Preclinical models have shown that it may influence blood pressure regulation, cardiac function, and kidney activity through activation of the cAMP–PKA pathway, enhanced blood flow, and modulation of inflammatory responses.

B7-33 is considered a promising research compound due to its potential relevance in ongoing and future scientific studies.

Laboratory reagent – for research purposes only.
This product is classified as a chemical reagent strictly for research use and must be handled by qualified professionals in laboratory conditions. It is not a dietary supplement, medicine, or food product and is not intended for human consumption. All information provided is for educational purposes only.